Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Early development of cyclin dependent kinase modulators
Autore:
Roy, KK; Sausville, EA;
Indirizzi:
NCI, Clin Trials Unit, Dev Therapeut Program, Div Canc Treatment & Diag, Bethesda, MD 20892 USA NCI Bethesda MD USA 20892 v Canc Treatment & Diag, Bethesda, MD 20892 USA
Titolo Testata:
CURRENT PHARMACEUTICAL DESIGN
fascicolo: 16, volume: 7, anno: 2001,
pagine: 1669 - 1687
SICI:
1381-6128(200111)7:16<1669:EDOCDK>2.0.ZU;2-#
Fonte:
ISI
Lingua:
ENG
Soggetto:
RNA-POLYMERASE-II; BREAST-CARCINOMA CELLS; DNA-DAMAGE CHECKPOINT; NATURAL PRODUCT HYMENIALDISINE; CDK-ACTIVATING KINASE; ACTIVITY IN-VIVO; FACTOR P-TEFB; PROTEIN-KINASE; SELECTIVE INHIBITOR; TUMOR-SUPPRESSOR;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
190
Recensione:
Indirizzi per estratti:
Indirizzo: Roy, KK NCI, Clin Trials Unit, Dev Therapeut Program, Div Canc Treatment &Diag, 10 Ctr Dr,Bldg 10,Room 6N 113, Bethesda, MD 20892 USA NCI 10 Ctr Dr,Bldg 10,Room 6N 113 Bethesda MD USA 20892 20892 USA
Citazione:
K.K. Roy e E.A. Sausville, "Early development of cyclin dependent kinase modulators", CUR PHARM D, 7(16), 2001, pp. 1669-1687

Abstract

The protein kinase family presents remarkable opportunities for drug discovery and development targeting mainly to the ATP binding cleft. Cyclin-dependent kinases CDKs control the cell division in by controlling its sub phases. The regulation of CDKs is altered in a number of tumor types, and therefore CDKs are a particularly attractive target group of kinases with reference to proliferative disorders including cancer, but also extending to graft stenosis, and autoimmune disorders. Screening of chemical modulators of CDKs that modulate aberrant CDK activity might be beneficial for cancer therapy by directly inhibiting kinase activity, or influencing cell cycle "checkpoint" function, which is mediated through effects of exogenous cellular regulators of CDK activity. In this regard small molecule modulators such asflavopiridol and UCN-01 are in early clinical trials. Other more selectivemodulators of CDK function are being actively sought, and initial results with flavopiridol analogs, indirubins, paullones, and purine-based inhibitors will be considered.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 11/07/20 alle ore 07:02:38